Preferred Label : Tisotumab Vedotin;
NCIt synonyms : HuMax-TF-ADC; Tisotumab Vedotin-tftv;
NCIt definition : An antibody-drug conjugate (ADC) comprised of tisotumab, a monoclonal antibody against
human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker,
to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule
disrupting agent, with potential antiangiogenic, anticoagulant and antineoplastic
activities. Upon administration of tisotumab vedotin, the tisotumab moiety binds to
cell surface TF and is internalized. Tisotumab binds to factor VIIa (FVIIa), which
interferes with the activation of factor X (FX) into FXa. This may prevent thrombin
formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis
and tumor cell proliferation. After internalization of the agent, the MMAE moiety
is released by proteolytic cleavage. It then binds to tubulin and inhibits its polymerization,
which results in G2/M phase arrest and apoptosis. TF, a transmembrane protein and
initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor-resident
endothelial cells. Expression of TF is correlated with metastasis, angiogenesis, tumor
cell growth and tumor-associated thrombosis.;
UNII : T41737F88A;
CAS number : 1418731-10-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1418731-10-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Tivdak;
NCI Metathesaurus CUI : CL455237;
Codes from synonyms : 71307;
Origin ID : C113164;
UMLS CUI : C4724800;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
